Table 2

Agreement on the use of BZD assessed by using a 10 cm line of visual analogue scale from totally disagree to totally agree*

Issues

Totally disagree, n (%)

Disagree, n (%)

Neutral, n (%)

Agree, n (%)

Totally agree, n (%)

1. For clinically significant insomnia

2 (3.6)

1 (1.8)

11 (20.0)

14 (25.5)

27 (49.1)

2. For clinically significant anxiety

7 (12.7)

4 (7.3)

10 (18.2)

15 (27.3)

19 (34.5)

3. For clinically significant depression

16 (29.1)

11 (20.0)

12 (21.8)

5 (9.1)

11 (20.0)

4. For regular use of less than 1 week

2 (3.6)

1 (1.8)

8 (14.5)

13 (23.6)

31 (56.4)

5. For regular use of 1 week – 1 month

15 (27.3)

2 (3.6)

12 (21.8)

15 (27.3)

11 (20.0)

6. For regular use of more than 1 month – 4 months

28 (50.9)

10 (18.2)

8 (14.5)

5 (9.1)

4 (7.3)

7. For regular use of more than 4 months – 6 months

39 (70.9)

9 (16.4)

4 (7.3)

1 (1.8)

2 (3.6)

8. For regular use of more than 6 months

47 (85.5)

4 (7.3)

3 (5.5)

0 (0.0)

1 (1.8)

*A VAS score of 0.00–1.9, 2.0–3.9, 4.0–6.0, 6.1–8.0, and 8.1–10.0 were classified as totally disagree, disagree, neutral, agree, and totally agree

Srisurapanont et al. BMC Family Practice 2005 6:27   doi:10.1186/1471-2296-6-27